What Is Vyleesi? (Mechanism, Uses & FDA Approval)

Fewer than 10% of women with hypoactive sexual desire disorder (HSDD) who try hormone therapy report sustained improvement beyond six months. Not because the diagnosis is wrong, but because most HSDD cases involve melanocortin pathway disruption that estrogen and testosterone cannot address. Vyleesi targets a completely different biological system.

We've worked with researchers studying melanocortin receptor agonists for years. The gap between understanding Vyleesi as "a shot for low libido" versus understanding its actual mechanism is the difference between managing expectations realistically and being blindsided by side effects or non-response.

What is Vyleesi and how does it work?

Vyleesi (bremelanotide) is an FDA-approved melanocortin receptor agonist administered as a subcutaneous injection for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It activates melanocortin receptors (MC1R and MC4R) in the central nervous system, triggering a cascade that modulates sexual desire independently of hormonal pathways. Unlike daily medications, Vyleesi is taken on-demand at least 45 minutes before anticipated sexual activity, with effects lasting up to 24 hours.

Vyleesi is not a hormone. It's not a neurotransmitter reuptake inhibitor. It's not a vasodilator. It works through melanocortin pathways. The same receptor family involved in skin pigmentation, appetite regulation, and inflammatory response. The reason this matters: if your HSDD stems from hormonal imbalance, thyroid dysfunction, or medication side effects, Vyleesi may not address the root cause. The drug works best when melanocortin signaling is intact but underactive. This article covers exactly how Vyleesi functions at the receptor level, who qualifies for treatment under FDA labeling, what the clinical trial data actually shows, and what preparation mistakes cause the most common adverse events.

How Vyleesi Works: Melanocortin Receptor Activation

Vyleesi is a synthetic peptide analog of alpha-melanocyte-stimulating hormone (α-MSH), the endogenous ligand for melanocortin receptors. When injected subcutaneously, bremelanotide crosses the blood-brain barrier and binds primarily to MC3R and MC4R receptors in the hypothalamus and brainstem. Regions that regulate sexual motivation, reward processing, and autonomic arousal. This binding triggers intracellular signaling through cyclic AMP (cAMP) pathways, which in turn modulate dopamine and norepinephrine release in areas associated with sexual desire.

The mechanism is fundamentally different from flibanserin (Addyi), the only other FDA-approved medication for HSDD. Flibanserin acts as a serotonin receptor agonist/antagonist and requires daily dosing to maintain steady-state plasma levels. Vyleesi, by contrast, works acutely. Receptor activation peaks 60–90 minutes post-injection and declines over the following 12–18 hours. Clinical pharmacokinetics show a half-life of approximately 2.7 hours, but subjective effects (increased desire, genital arousal) persist longer due to downstream neurochemical changes that outlast the drug's plasma presence.

One mechanism most overviews miss: MC4R activation in the hypothalamus also modulates autonomic nervous system tone, increasing sympathetic outflow that contributes to physical arousal (increased heart rate, blood flow to genital tissue). This is why some patients report not just psychological desire but measurable physiological changes. Vyleesi affects both branches of the arousal response. In our work with peptide researchers, we've seen this dual-action pattern replicated across melanocortin analogs used in entirely different therapeutic contexts, from appetite suppression to anti-inflammatory applications like Thymalin, which targets immune modulation through related peptide pathways.

FDA Approval, Clinical Trial Data, and Efficacy Endpoints

Vyleesi received FDA approval in June 2019 based on results from two Phase 3 randomized, double-blind, placebo-controlled trials (RECONNECT trials) involving 1,267 premenopausal women diagnosed with generalized acquired HSDD. The primary endpoints were change from baseline in (1) desire domain score on the Female Sexual Function Index (FSFI) and (2) distress related to low sexual desire on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO).

Results: women receiving Vyleesi 1.75mg subcutaneous injection showed statistically significant improvement in both endpoints compared to placebo at 24 weeks. Mean change in FSFI desire domain score was +0.3 to +0.4 points for Vyleesi versus +0.2 for placebo. Distress scores improved by 8–10 points on Vyleesi versus 5–6 points on placebo. These effect sizes are modest but clinically meaningful. A 0.3-point improvement in FSFI desire score correlates with patients reporting "somewhat better" or "better" subjective desire during post-trial interviews.

The limitations: approximately 25–30% of women treated with Vyleesi in clinical trials discontinued due to adverse events, primarily nausea (40% incidence) and flushing (20% incidence). These are melanocortin receptor–mediated effects. MC1R activation in skin causes vasodilation (flushing), while MC4R activation in the brainstem's area postrema triggers nausea signaling. Most nausea occurs within the first two hours post-injection and resolves within 4–6 hours, but for some patients it's severe enough to outweigh the benefit.

Here's the honest answer: Vyleesi works, but it doesn't work dramatically. It's not a libido "switch." Clinical trial data shows about 25% of women experience meaningful improvement beyond placebo. Meaning three out of four patients either see minimal benefit or discontinue due to side effects. If you're considering Vyleesi, you're essentially committing to a 2–3 month trial period to determine if you're a responder. Non-responders typically know by injection four or five.

Vyleesi vs Flibanserin vs PT-141: Mechanism Comparison

Patients often ask how Vyleesi compares to other HSDD treatments and to PT-141, the research peptide from which bremelanotide was derived. The comparison table below breaks down the key differences.

The professional assessment that most physicians won't say outright: PT-141 and Vyleesi are the same molecule. PT-141 was the investigational name during clinical development; bremelanotide is the INN (international nonproprietary name); Vyleesi is the brand name. Patients sometimes believe PT-141 is "stronger" or "purer". It's not. The only difference is regulatory oversight and delivery format. Vyleesi comes in a pre-filled autoinjector pen dosed at 1.75mg; PT-141 for research is typically sold as lyophilized powder requiring reconstitution with bacteriostatic water. The risk with non-FDA products is dosing variability and contamination. Melanocortin peptides are notoriously unstable once reconstituted and degrade rapidly if stored improperly.

What If: Vyleesi Scenarios

What If I Experience Severe Nausea After the First Injection?

Take an antiemetic (ondansetron 4–8mg or promethazine 25mg) 30 minutes before your next Vyleesi dose. Premedication with a 5-HT3 receptor antagonist significantly reduces nausea severity in clinical practice, though this strategy wasn't formally tested in the RECONNECT trials. If nausea persists beyond the first three injections despite premedication, you're likely a non-responder to melanocortin agonists. Continuing is unlikely to provide benefit that outweighs the adverse event burden.

What If Vyleesi Doesn't Work After Four or Five Uses?

You are probably not a melanocortin pathway responder. Approximately 50–60% of women with HSDD show minimal to no improvement on Vyleesi, often because their low desire stems from hormonal imbalance, relationship stressors, or medication side effects (especially SSRIs, which blunt dopamine signaling downstream of melanocortin activation). If Vyleesi fails, the next diagnostic step is evaluating free testosterone, thyroid function (TSH, free T3, free T4), and reviewing current medications for libido-suppressing agents. Some patients respond better to low-dose testosterone therapy or switching from an SSRI to bupropion, which enhances rather than inhibits dopamine and norepinephrine.

What If I Want to Use Vyleesi More Than Once Per Week?

FDA labeling recommends no more than eight doses per month and no more than one dose within 24 hours. The constraint is not addiction risk. Melanocortin agonists are not habit-forming. But rather the cumulative adverse event burden (nausea, transient blood pressure elevation) and the lack of long-term safety data for frequent use. Some prescribers allow twice-weekly dosing in patients who tolerate the medication well and show clear benefit, but insurance coverage often restricts quantity to eight autoinjector pens per 28 days.

The Clinical Truth About Vyleesi

Here's the honest answer most marketing materials avoid: Vyleesi works for about one in four women who try it, and even for responders, the effect is not a dramatic restoration of youthful libido. It's a modest, statistically significant improvement that patients describe as "somewhat better" rather than "transformative." The 40% nausea rate is not an exaggeration or a worst-case scenario; it's the base rate observed in controlled trials. For patients who discontinue, the decision usually comes down to whether a marginal increase in desire justifies feeling nauseated for three hours every time you use it.

The reason Vyleesi matters despite these limitations: it's one of only two FDA-approved pharmacological treatments for HSDD, and for the subset of patients whose low desire is driven by melanocortin pathway dysfunction, it's the only option that directly addresses the underlying mechanism. Women who fail hormone therapy, who cannot tolerate flibanserin, or who have HSDD in the context of normal hormone levels are the population most likely to benefit. If you're in that group, Vyleesi is worth a structured 2–3 month trial under physician supervision.

For researchers exploring melanocortin analogs in other therapeutic contexts, the Vyleesi experience highlights a recurring theme: melanocortin receptor agonists produce reproducible biological effects but with a high adverse event burden that limits real-world adherence. This pattern holds true across appetite regulation (Melanotan 2), sexual function, and even anti-inflammatory applications. At Real Peptides, we see this trade-off in our work supplying research-grade melanocortin peptides to labs studying these pathways. The science is solid, but translating it into tolerable therapies remains the bottleneck. You can explore the broader peptide research landscape through our full collection of compounds synthesized to the same exacting standards.

Vyleesi is not a miracle drug. It's a precision tool for a specific subset of HSDD, and like all precision tools, it works brilliantly when applied to the right problem and fails when forced onto the wrong one. If melanocortin pathway dysfunction is your issue, Vyleesi is the most direct solution available. But only diagnostic clarity will tell you if that's actually what you're treating.